MedTrace Logo

Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma

NCT01543802 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2021-01-26

No results posted yet for this study

Summary

The purpose of this study is to examine if a short-term treatment with pazopanib, an oral drug inhibiting the growth of blood vessel, can reduce the metabolism of soft-tissue sarcomas and thus facilitate their resection when given prior to surgery. Moreover, the study assesses the prognostic and predictive value of several new biomarkers (endothelial progenitor cells, soluble vascular epithelial growth factor),

Conditions

  • Sarcoma, Soft-tissue

Interventions

DRUG

pazopanib

Treatment with pazopanib 800 mg qd for 21 days followed by resection of the tumor after a 7-14 days break

Sponsors & Collaborators

  • Universitätsmedizin Mannheim

    collaborator OTHER

  • Klinikum Frankfurt Höchst

    collaborator OTHER

  • German Cancer Research Center

    collaborator OTHER

  • GlaxoSmithKline

    collaborator INDUSTRY

  • University Hospital Heidelberg

    collaborator OTHER

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Peter Hohenberger, MD · University Hospital Mannheim, Department of Surgery

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01543802 on ClinicalTrials.gov